M61: Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi, 1st Edition

12 Pages·2017·2.75 MB·English

1st Edition
M61 E
Performance Standards for AntifLungal
Susceptibility Testing of Filamentous Fungi
P
M
A
S
This document provides updated quality control tables for
the Clinical and Laboratory Standards Institute antifungal
susceptibility testing documents M38 and M51.
A CLSI supplement for global application.
Clinical and Laboratory Standards Institute
Setting the standard for quality in medical laboratory testing around the world.
The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings
together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a
common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory
standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global
applicability.

E
Consensus Process
Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the
development of all CLSI documents. It does not always connote unanimous agreement but does mean that the
participants in the development of a consensus document have considered and resLolved all relevant objections
and accept the resulting agreement.

Commenting on Documents
P
CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies,
procedures, methods, and protocols affecting the laboratory or health care.
CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants
M
in the reviewing and commenting process. At the end of each comment period, the committee that developed
the document is obligated to review all comments, respond in writing to all substantive comments, and revise the
draft document as appropriate.
Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on
any document. All comments are managed according to the consensus process by a committee of experts.
A

Appeal Process
When it is believed that an objection has not been adequately considered and responded to, the process for
appeal, documented in theS CLSI Standards Development Policies and Processes, is followed.
All comments and responses submitted on draft and published documents are retained on file at CLSI and are
available upon request.
Get Involved—Volunteer!
Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get
involved in the revision process? Or maybe you see a need to develop a new document for an emerging
technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents
to improve the standards that affect your own work, you will play an active role in improving public health across
the globe.
For additional information on committee participation or to submit comments, contact CLSI.
Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
[email protected]
M61, 1st ed.
November 2017
Replaces M51-S1
Performance Standards for Antifungal Susceptibility Testing of
Filamentous Fungi

Barbara D. Alexander, MD, MHS E
Gary W. Procop, MD, MS
Philippe Dufresne, PhD (RMCCM)
Jeff Fuller, PhD, FCCM, D(ABMM)
Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
L
Kimberly E. Hanson, MD, MHS
Denise Holliday, MT(ASCP)
Nicole M. Holliday, BA
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
P
Audrey N. Schuetz, MD, MPH, D(ABMM)
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)

M

Abstract

Clinical and Laboratory Standards Institute document M61—Performance Standards for Antifungal Susceptibility Testing of
Filamentous Fungi provides information to use with the testing procedures in CLSI documents M381 and M51.2

A
The tabular information in this document includes the most current information for antifungal agent selection, results interpretation,
and quality control and is valid only when the methodology is followed as described in the current editions of CLSI documents
M381 and M51.2 Any previously published tables should be replaced with these new tables. Changes since the last edition appear
in boldface type.

Clinical and LaboratoryS Standards Institute (CLSI). Performance Standards for Antifungal Susceptibility Testing of Filamentous
Fungi. 1st ed. CLSI supplement M61 (ISBN 1-56238-832-0 [Print]; ISBN 1-56238-833-9 [Electronic]). Clinical and Laboratory
Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two
or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given
document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline,
users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI
catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one,
or to request a copy of the catalog, contact us at: Telephone: [phone]; Fax: [phone]; E-Mail:
[email protected]; Website: www.clsi.org.
M61, 1st ed.

Copyright ©2017 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of
content from a CLSI copyrighted standard, guideline, companion product, or other material requires express
written consent from CLSI. All rights reserved. Interested parties may send permission requests to
E
[email protected].

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of
this publication for use in its laboratory procedures manual at a single site. To request permission to use
this publication in any other manner, e-mail [email protected].
L

Suggested Citation

CLSI. Performance Standards for Antifungal Susceptibility TPesting of Filamentous Fungi. 1st ed. CLSI
supplement M61. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

Previous Edition:
M51-S1: May 2010
M

A

S

ISBN 1-56238-832-0 (Print)
ISBN 1-56238-833-9 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic) Volume 37, Number 16

ii
M61, 1st ed.

Contents

Abstract .................................................................................................................................................... i
Committee Membership ........................................................................................................................ iii
Foreword .............................................................................................................................................. vii
Abbreviations and Acronyms ............................................................................................................. viii
Table 1. Recommended Minimal Inhibitory Concentration or Minimal Effective Concentrations
and Modes for Quality Control and Reference Strains for Broth Dilution Antifungal SusEceptibility
Testing Procedures .................................................................................................................................. 1
Table 2. Recommended Zone Diameter Limits and Modes for Quality Control and Reference
Strains for Disk Diffusion Antifungal Susceptibility Testing Procedures .............................................. 4
Table 3. Solvents and Diluents for Preparation of Stock Solutions of AntifLungal Agents ..................... 6
References ............................................................................................................................................... 7
The Quality Management System Approach .......................................................................................... 8
P
Related CLSI Reference Materials ......................................................................................................... 9

M
A
S
v
M61, 1st ed.

Foreword

Users of CLSI documents M381 and M512 and this document should recognize that the standard methods
described in CLSI documents are reference methods. These methods may be used for:

 Routine antifungal testing of patient isolates to guide therapy
 Evaluating commercial devices that will be used in medical laboratories
 Testing new agents or systems by drug or device manufacturers

Results generated by reference methods, such as those provided in CLSI documents, may be used by
E
regulatory authorities to evaluate commercial susceptibility testing device performance as part of the
approval process. Regulatory clearance indicates that the commercial susceptibility testing device provides
results that are substantially equivalent to those generated using reference methods for the organisms and
antimicrobial agents described in the device manufacturer’s approved package insert.
L
NOTE: Fungal taxonomy has undergone major changes in recent years with the dual (asexual and sexual
stages) nomenclature having been abolished and the constant reclassification and renaming of fungal
species that result from improved molecular characterization.3 Species names listed in CLSI document
M381 were revised to reflect the most recent taxonomic changePs based on classification according to DNA
bar coding at the time of publication. For more information regarding updated fungal species
reclassification, refer to publicly available information.4

Overview of Changes
M

This document replaces the previous edition of the approved supplement M51-S1, published in 2010, and
incorporates information from CLSI document M38-A2. Several changes were made in this edition,
including:

 General:
A
– Combined supplemental information from M38-A2 (broth dilution susceptibility testing of
filamentous fungi) and M51-S1 (disk diffusion testing of filamentous fungi) into one informational
supplement, which has been recoded as M61

– Deleted theS glossary with abbreviations, routes of administration, and drug classes for antifungal
agents

 Tables:
– Moved Table 1 from M38-A2 (Solvents and Diluents for Preparation of Stock Solutions of
Antifungal Agents) to M61, where it is now Table 3, and added information for isavuconazole

– Updated QC ranges for itraconazole and posaconazole for Candida parapsilosis and added QC
ranges for isavuconazole in Table 1

– Moved Table 4 from M38-A2 (Recommended MIC or MEC Limits for QC and Reference Strains
for Broth Dilution Procedures) to M61, where it is now Table 1, and revised the title
(Recommended Minimal Inhibitory Concentration or Minimal Effective Concentrations and
Modes for Quality Control and Reference Strains for Broth Dilution Antifungal Susceptibility
Testing Procedures)

– Moved Table 1 from M51-S1 (Tentative Zone Diameter Epidemiological Cutoff Values [ECV] and
Corresponding Minimal Inhibitory Concentration [MIC] or Minimal Effective Concentration
[MEC] for Filamentous Fungi) to CLSI document M59,5 the supplement to CLSI document M576
vii
M61, 1st ed.

Table 1. Recommended Minimal Inhibitory Concentration or Minimal Effective
Concentrations and Modes for Quality Control and Reference Strains for Broth
Dilution Antifungal Susceptibility Testing Procedures

MICs/
MIC/ MECs
MIC/MEC MEC Within Incubation
Antifungal Range, Mode, Range, Time,
Organism Purpose Agent µg/mL µg/mL % hours*
Paecilomyces variotii QC Amphotericin B 1–4 2 100 48
ATCC®† MYA-36301,2 Isavuconazole 0.06–0.5 0.12 96.7 48
E
Itraconazole 0.06–0.5 0.12 100 48
Posaconazole 0.03–0.25 0.06 99.5 48
Voriconazole 0.015– 0.06 100 48
0.12
Reference (MEC)‡ Anidulafungin ≤0.015 N/A 100 24

L
Candida parapsilosis QC Amphotericin B 0.5–4 2 91.7 48
ATCC® 220193,4 Anidulafungin 0.5–2 1 95 24
Caspofungin 0.25–1 0.5 96.7 24
Caspofungin 0.5–4 1 92.9 48
P
Fluconazole 1–4 2 98.1 48
Flucytosine 0.12–0.5 0.25 97.9 48
Isavuconazole 0.03–0.12 0.03 98.3 48
Itraconazole 0.06–0.5 0.25 97.5 48
Ketoconazole 0.06–0.5 0.12 98.3 48
M
Micafungin 0.5–4 1 100 24
Posaconazole 0.03–0.25 0.12 98.8 48
Ravuconazole 0.03–0.25 0.06 98.3 48
Voriconazole 0.03–0.25 0.06 100 48
Candida krusei QC Amphotericin B 1–4 2 100 48
ATCC® 62583,4 Anidulafungin 0.03–0.12 0.06 97.5 48
A Caspofungin 0.12–1 0.5 98.8 24
Caspofungin 0.25–1 0.5 97.5 48
Fluconazole 16–128 32 100 48
Flucytosine 8–32 16 99.6 48
Isavuconazole 0.12–0.5 0.12 94.2 48
S
Itraconazole 0.25–1 0.5 100 48
Ketoconazole 0.25–1 0.5 99.6 48
Micafungin 0.12–0.5 0.25 99 48
Posaconazole 0.12–1 0.5 99.6 48
Ravuconazole 0.25–1 0.5 100 48
Voriconazole 0.12–1 0.5 100 48
Aspergillus flavus Reference Amphotericin B 0.5–4 ND 100 48
ATCC® 2043045,6,§ Itraconazole 0.25–0.5 ND 100 48
Posaconazole 0.06–0.5 ND 100 48
Ravuconazole 0.5–4 ND 100 48
Voriconazole 0.5–4 ND 100 48
QC Isavuconazole 0.5–4 1 95.8 48
A. flavus Reference Amphotericin B 1–8 2 98.8 48
ATCC® MYA-36311 Posaconazole 0.12–1 0.5 97.1 48
Voriconazole 0.5–2 1 98.3 48
Aspergillus fumigatus Reference Amphotericin B 0.5–4 2 98.7 48
ATCC® MYA-36261,2 Itraconazole 0.25–2 1 95.7 48
Voriconazole 0.25–1 0.5 100 48
Reference (MEC)‡ Anidulafungin ≤0.015 N/A 100 24

©Clinical and Laboratory Standards Institute. All rights reserved. 1
M61, 1st ed.

Table 1. (Continued)
MICs/
MIC/ MECs
MIC/MEC MEC Within Incubation
Antifungal Range, Mode, Range, Time,
Organism Purpose Agent µg/mL µg/mL % hours*
A. fumigatus Reference Amphotericin B 0.5–4 2 99.2 48
ATCC® MYA-36271 Itraconazole ≥16 ≥16 95 48

Voriconazole 0.25–1 0.5 99.2 48
Aspergillus terreus Reference Amphotericin B 2–8 4 98.3 48
ATCC® MYA-36331,2 Voriconazole 0.25–1 0.5 99.2 48
E
Reference (MEC)‡ Anidulafungin ≤0.015 N/A 99.6 24

Fusarium Reference Amphotericin B 2–8 4 99.6 48
verticillioides Itraconazole >16 >16 97.9 48

(moniliforme) Posaconazole 0.5–2 1 98.1 48
ATCC® MYA-36291,2 Voriconazole 1–4 2 100 48
L
F. verticillioides Reference (MIC) ‡ Anidulafungin >8 N/A 97.5 48

(moniliforme)
ATCC®† MYA-36291,2
Fusarium solani Reference (MIC)‡ Anidulafungin >8 N/A 96.7 48
P
ATCC® MYA-36362
Scedosporium Reference Amphotericin B 4–16 8 98.8 72
apiospermum Posaconazole 1–4 2 98.3 72
ATCC® MYA-36355,6 Voriconazole 0.5–2 1 100 72
S. apiospermum Reference (MEC)‡ Anidulafungin 1–4 2 96.7 48–72
M
ATCC® MYA-36342
Trichophyton Reference Ciclopirox 0.5–2 1 97.5 96
mentagrophytes¶ Griseofulvin 0.12–0.5 0.25 96.3 96
MRL 1957 Itraconazole 0.03–0.25 0.06 96.2 96
ATCC® MYA-44397 Posaconazole 0.03–0.25 0.06 95.2 96
Terbinafine 0.002– 0.004 97.9 96
A
0.008
Voriconazole 0.03–0.25 0.06 95.2 96
Trichophyton rubrum¶ Reference Ciclopirox 0.5–2 1 97.5 96
MRL 666 Fluconazole 0.5–4 1 95.2 96
ATCC® MYA-44387 Voriconazole 0.008– 0.015 96.1 96
S
0.06
* MIC ranges correspond to the indicated incubation time. In some cases, MIC ranges are also available by the macrodilution
method (48 hours only) and after 24 hours by the microdilution method.8-10 One of the QC isolates should be used per standard QC
testing procedures (see CLSI document M3811).

† ATCC® is a registered trademark of the American Type Culture Collection.

‡ Although the anidulafungin concentration range in the study was 0.015 to 32 µg/mL, off-scale MICs >32 µg/mL from that study

are reported in Table 1 as >8 µg/mL to be consistent with the recommended routine testing range for this compound.2

§ The MIC ranges for A. flavus ATCC® 204304 are based on data from a collaborative study5,6 that were not obtained according to
the CLSI document M2312 process. However, A. flavus is the only mould for which reproducible reference limits for ravuconazole
have been established, so it is included in Table 1.

¶ Ninety-six hours or until good growth (confluent hyphal growth covering the bottom of the well) is obtained in the growth control
well.13

Abbreviations: ATCC®, American Type Culture Collection; MEC, minimal effective concentration; MIC, minimal inhibitory
concentration; N/A, not applicable; ND, not determined; QC, quality control.

NOTE: Information in boldface type is new or modified since the previous edition.

2 ©Clinical and Laboratory Standards Institute. All rights reserved.
M61, 1st ed.

The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system (QMS) approach in
the development of standards and guidelines that facilitates project management, defines a document structure using
a template, and provides a process to identify needed documents. The QMS approach applies a core set of “quality
system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow
(ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework
for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

Organization Personnel Process Management Nonconforming Event Management
Customer Focus Purchasing and Inventory Documents and Records Assessments
E
Facilities and Safety Equipment Information Management Continual Improvement

M61 covers the QSE indicated by an “X.” For a description of the documents listed in the grid, please refer to the
Related CLSI Reference Materials section.

L
Organization Customer Focus Facilities and Safety Personnel Purchasing and Inventory Equipment Process Management PDocuments and Records Information Management Nonconforming vent Management Assessments Continual Improvement
E
X

M23
M38
M M51
M57
M59

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the
organization or entity provides. A laAboratory path of workflow consists of the sequential processes: preexamination,
examination, and postexamination and their respective sequential subprocesses. All laboratories follow these
processes to deliver their services, namely quality laboratory information.

M61 does not cover any medical laboratory path of workflow processes. For a description of the other documents
listed in the grid, pleaSse refer to the Related CLSI Reference Materials section.

Preexamination Examination Postexamination
Examination ordering Sample collection Sample transport Sample receipt and processing Examination Results review and follow-up Interpretation Results reporting and archiving Sample management
M38 M38 M38 M38 M38
M51 M51 M51 M51 M51
M59 M59 M59

8 ©Clinical and Laboratory Standards Institute. All rights reserved.
M61, 1st ed.

Related CLSI Reference Materials

M23 Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters. 4th ed., 2016.
This document discusses the necessary and recommended data for the selection of appropriate interpretive
criteria and quality control ranges for antimicrobial agents.

M38 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi.
3rd ed., 2017. This standard includes the antifungal agent selection, preparation of antifungal stock solutions
and dilutions for testing, test procedure implementation and interpretation, and quality control requirements for
susceptibility testing of filamentous fungi (moulds) that cause invasive and cutaneous fungal infections.

M51 Method for Antifungal Disk Diffusion Susceptibility Testing of NondermatophyteE Filamentous Fungi.
1st ed., 2010. This document describes the guidelines for antifungal susceptibility testing by the disk diffusion
method of nondermatophyte filamentous fungi (moulds) that cause invasive disease.

M57 Principles and Procedures for the Development of Epidemiological Cutoff Values for Antifungal
Susceptibility Testing. 1st ed., 2016. This guideline includes the criteria for developing and using
L
epidemiological cutoff values for guiding clinical decisions when testing fungal species and antifungal agent
combinations for which there are no breakpoints.

M59 Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 1st ed., 2016. This document includes
the epidemiological cutoff value and quality control tables developed according to criteria provided in the
P
Clinical and Laboratory Standards Institute guideline M57.

M
A
S

 CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the
most current editions.

©Clinical and Laboratory Standards Institute. All rights reserved. 9